RUCAM in drug and herb induced liver injury: The update

International Journal of Molecular Sciences

Volumn 17, Issue 1, 2016, Pages

  Danan, Gaby ^a   Teschke, Rolf ^b  

^a Pharmacovigilance Consultancy   (France)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Causality assessment; CIOMS; Dietary supplements; Drug hepatotoxicity; Drug induced liver injury; Drugs; Herb induced liver injury; Herbal hepatotoxicity; Herbs; RUCAM

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PLANT MEDICINAL PRODUCT;

ADDISON DISEASE; ALCOHOL CONSUMPTION; CLINICAL ASSESSMENT TOOL; CYTOMEGALOVIRUS; DIET SUPPLEMENTATION; EPSTEIN BARR VIRUS; HEMOCHROMATOSIS; HEPATITIS A VIRUS; HEPATITIS E VIRUS; HUMAN; LIVER TOXICITY; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PREGNANCY; REVIEW; ROUSSEL UCLAF CAUSALITY ASSESSMENT METHOD; SENSITIVITY AND SPECIFICITY; TOXIC HEPATITIS; CHEMICAL AND DRUG INDUCED LIVER INJURY; CLASSIFICATION; COMPARATIVE STUDY; ORGAN DYSFUNCTION SCORE; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

CHEMICAL AND DRUG INDUCED LIVER INJURY; HUMANS; ORGAN DYSFUNCTION SCORES; PLANT PREPARATIONS; SEVERITY OF ILLNESS INDEX;

EID: 84951788964     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17010014     Document Type: Review

References (173)

1. Andrade, R.J.; Lucena, M.I.; Fernández, M.C.; Pelaez, G.; Pachkoria, K.; García-Ruiz, E.; García-Muñoz, B.; Gonzalez-Grande, R.; Pizarro, A.; Durán, J.A.; et al. spanish group for the study of drug-induced liver disease. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005, 129, 512-521. [CrossRef] [PubMed]
2. Andrade, R.J.; Lucena, M.I.; Kaplowitz, N.; García-Muñoz, B.; Borraz, Y.; Pachkoria, K.; García-Cortés, M.; Fernández, M.C.; Pelaez, G.; Rodrigo, L.; et al. Outcome of acute idiosyncratic drug-induced liver injury: Long term follow-up in a hepatotoxicity registry. Hepatology 2006, 44, 1581-1588. [CrossRef] [PubMed]
3. Chalasani, N.; Fontana, R.J.; Bonkovsky, H.L.; Watkins, P.B.; Davern, T.; Serrano, J.; Yang, H.; Rochon, J. Drug-induced liver injury network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135, 1924-1934. [CrossRef] [PubMed]
4. Liss, G.; Lewis, J.H. Drug-induced liver injury: What was new in 2008? Expert Opin. Drug Metab. Toxicol. 2009, 5, 843-860. [CrossRef] [PubMed]
5. Björnsson, E.; Jacobsen, E.I.; Kalaitzakis, E. Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing. J. Hepatol. 2012, 56, 374-380. [CrossRef] [PubMed]
6. Chalasani, N.; Bonkovsky, H.L.; Fontana, R.; Lee, W.; Stolz, A.; Talwalkar, J.; Reddy, K.R.; Watkins, P.B.; Navarro, V.; Barnhart, H.; et al. Features and outcomes of 889 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology 2015, 148, 1340-1352. [CrossRef] [PubMed]
7. Teschke, R.; Andrade, R. Editorial. Drug-induced liver injury: Expanding our knowledge by enlarging population analysis with prospective and scoring causality assessment. Gastroenterology 2015, 148, 1271-1273. [CrossRef] [PubMed]
8. Danan, G.; Bénichou, C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J. Clin. Epidemiol. 1993, 46, 1323-1330. [CrossRef]
9. Bénichou, C.; Danan, G.; Flahault, A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge. J. Clin. Epidemiol. 1993, 46, 1331-1336. [CrossRef]
10. Seeff, K.B. Herbal hepatotoxicity. Clin. Liver Dis. 2007, 11, 577-596. [CrossRef] [PubMed]
11. Teschke, R.; Schwarzenboeck, A.; Eickhoff, A.; Frenzel, C.; Wolff, A.; Schulze, J. Clinical and causality assessment in herbal hepatotoxicity. Expert Opin. Drug Saf. 2013, 12, 330-366. [CrossRef] [PubMed]
12. Bunchorntavakul, C.; Reddy, K.R. Review article: Herbal and dietary supplement hepatotoxicity. Aliment. Pharmacol. Ther. 2013, 37, 3-17. [CrossRef] [PubMed]
13. Navarro, V.J.; Barnhart, H.; Bonkovsky, H.L.; Davern, T.; Fontana, R.J.; Grant, L.; Reddy, K.R.; Seeff, L.B.; Serrano, J.; Sherker, A.H.; et al. Liver injury from herbals and dietary supplements in the U.S. drug-induced liver injury network. Hepatology 2014, 60, 1399-1408. [CrossRef] [PubMed]
14. Teschke, R.; Eickhoff, A. Herbal hepatotoxicity in traditional and modern medicine: Actual key issues and new encouraging steps. Front. Pharmacol. 2015, 6, 1-40. [CrossRef] [PubMed]
15. Teschke, R.; Eickhoff, A.; Schwarzenboeck, A.; Schmidt-Taenzer, W.; Genthner, A.; Frenzel, C.; Wolff, A.; Schulze, J. Clinical review: Herbal hepatotoxicity and the call for systematic data documentation of individual cases. J. Liver Clin. Res. 2015, 2, 1008.
16. Teschke, R.; Schulze, J.; Eickhoff, A.;Wolff, A.; Frenzel, C. Mysterious Hawaii liver disease case-Naproxen overdose as cause rather than OxyELITE Pro? J. Liver Clin. Res. 2015, 2, 1013.
17. Teschke, R.; Schwarzenboeck, A.; Frenzel, C.; Schulze, J.; Eickhoff, A.; Wolff, A. The mystery of the Hawaii liver disease cluster in summer 2013, a pragmatic and clinical approach to solve the problem. Ann. Hepatol. 2016, 15, 91-118. [CrossRef]
18. Aithal, G.P.; Watkins, P.B.; Andrade, R.J.; Larrey, D.; Molokhia, M.; Takikawa, H.; Hunt, C.M.; Wilke, R.A.; Avigan, M.; Kaplowitz, N.; et al. Case definition and phenotype standardization in drug-induced liver injury. Clin. Pharmacol. Ther. 2011, 89, 806-815. [CrossRef] [PubMed]
19. Urban, T.J.; Daly, A.K.; Aithal, G.P. Genetic basis of drug-induced liver injury: Present and future. Semin. Liver Dis. 2014, 34, 123-133. [CrossRef] [PubMed]
20. Andrade, R.J.; Robles, M.; Ulzurrun, E.; Lucena, M.I. Drug-induced liver injury: Insights from genetic studies. Pharmacogenomics 2009, 10, 1467-1487. [CrossRef] [PubMed]
21. Sgro, C.; Clinard, F.; Ouazir, K.; Chanay, H.; Allard, C.; Guilleminet, C.; Lenoir, C.; Lemoine, A.; Hillon, P. Incidence of drug-induced hepatic injuries: A French population-based study. Hepatology 2002, 36, 451-455. [CrossRef] [PubMed]
22. Lammert, C.; Einarsson, S.; Saha, C.; Niklasson, A.; Bjornsson, E.; Chalasani, N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: Search for signals. Hepatology 2008, 47, 2003-2009. [CrossRef] [PubMed]
23. Chen, M.; Borlak, J.; Tong,W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013, 58, 388-396. [CrossRef] [PubMed]
24. Khandelwal, N.; James, L.P.; Sanders, C.; Larson, A.M.; Lee, W.M. The acute liver failure study group. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology 2011, 53, 567-576. [CrossRef] [PubMed]
25. Li, C.; Liang, X.S.; Li, C.Z. Sinusoidal obstruction syndrome associated with the ingestion of gynura root. Clin. Toxicol. 2010, 48, 962-964. [CrossRef] [PubMed]
26. eschke, R.;Wolff, A.; Frenzel, C.; Schulze, J. Review article: herbal hepatotoxicity-An update on traditional Chinese medicine preparations. Aliment Pharmacol. Ther. 2014, 40, 32-50. [CrossRef] [PubMed]
27. Larrey, D.; Faure, S. Herbal medicine hepatotoxicity: A new step with development of specific biomarkers. J. Hepatol. 2011, 54, 599-601. [CrossRef] [PubMed]
28. Aithal, G.P.; Rawlins, M.D.; Day, C.P. Accuracy of hepatic adverse drug reaction reporting in one English health region. Br. Med. J. 1999, 319, 1541. [CrossRef]
29. Dalton, H.R.; Fellows, H.J.; Stableforth, W.; Joseph, M.; Thurairajah, P.H.; Warshow, U.; Hazeldine, S.; Remnarace, R.; Ijaz, S.; Hussaini, S.H.; et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment. Pharmacol. Ther. 2007, 26, 1429-1435. [CrossRef] [PubMed]
30. Davern, T.J.; Chalasani, N.; Fontana, R.J.; Hayashi, P.H.; Protiva, P.; Kleiner, D.E.; Engle, R.E.; Nguyen, H.; Emerson, S.U.; Purcell, R.H.; et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011, 141, 1665-1672. [CrossRef] [PubMed]
31. Teschke, R.; Frenzel, C.;Wolff, A.; Eickhoff, A.; Schulze, J. Drug induced liver injury: Accuracy of diagnosis in published reports. Ann. Hepatol. 2014, 13, 248-255. [PubMed]
32. Teschke, R.; Schulze, J.; Schwarzenboeck, A.; Eickhoff, A.; Frenzel, C. Herbal hepatotoxicity: Suspected cases assessed for alternative causes. Eur. J. Gastroenterol. Hepatol. 2013, 25, 1093-1098. [CrossRef] [PubMed]
33. National Institutes of Health (NIH) and LiverTox: Causality. Available online: http://livertox.nlm.nih. gov/Causality.html (accessed on 7 November 2015).
34. García-Cortés, M.; Stephens, C.; Lucena, M.I.; Fernández-Castañer, A.; Andrade, R.J. Causality assessment methods in drug induced liver injury: Strengths and weaknesses. J. Hepatol. 2011, 55, 683-691. [CrossRef] [PubMed]
35. Teschke, R.; Wolff, A.; Frenzel, C.; Schwarzenboeck, A.; Schulze, J.; Eickhoff, A. Drug and herb induced liver injury: Council for international organizations of medical sciences scale for causality assessment. World J. Hepatol. 2014, 6, 17-32. [PubMed]
36. Teschke, R.; Eickhoff, A.; Schulze, J. Drug and herb induced liver injury in clinical and translational hepatology: Causality assessment methods, quo vadis? J. Clin. Transl. Hepatol. 2013, 1, 59-74. [CrossRef] [PubMed]
37. Bégaud, B.; Evreux, J.C.; Jouglard, J.; Lagier, G. Unexpected or toxic drug reaction assessment (imputation). Actualization of the method used in France. Therapie 1985, 40, 111-118. [PubMed]
38. Danan, G.; Bénichou, C.; Begaud, B.; Biour, M.; Couzigou, P.; Evreux, J.C.; Lagier, G.; Berthelot, P.; Benhamou, J.P. Critères dimputation dune hépatite aiguë à un médicament. Résultats de réunions de consensus. Gastroenterol. Clin. Biol. 1987, 11, 581-585. [PubMed]
39. Danan, G. Consensus meetings on: Causality assessment of drug-induced liver injury. J. Hepatol. 1988, 7, 132-136. [CrossRef]
40. Bénichou, C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J. Hepatol. 1990, 11, 272-276. [PubMed]
41. Maria, V.A.J.; Victorino, R.M.M. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997, 26, 664-669. [CrossRef] [PubMed]
42. Takikawa, H.; Takamori, Y.; Kumagi, T.; Onji, M.;Watanabe, M.; Shibuya, A.; Hisamochi, A.; Kumashiro, R.; Ito, T.; Mitsumoto, Y.; et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. Hepatol. Res. 2003, 27, 192-195. [CrossRef]
43. Takikawa, H. Recent status of drug-induced liver injury and its problems in Japan. Jpn. Med. Assoc. J. 2010, 53, 243-247.
44. Hutchinson, T.A.; Lane, D.A. Assessing methods for causality assessment of suspected adverse drug reactions. J. Clin. Epidemiol. 1989, 42, 5-16. [CrossRef]
45. Hoofnagle, J.H.; Nelson, K.E.; Purcell, R.H. Review article: Hepatitis E. N. Engl. J. Med. 2012, 367, 1237-1244. [CrossRef] [PubMed]
46. National Institutes of Health (NIH) and LiverTox: Agents Included in LiverTox by Drug Class. Available online: http://livertox.nlm.nih.gov/index.html (accessed on 7 November 2015).
47. National Institutes of Health (NIH) and LiverTox: Drug Record. Herbals and Dietary Supplements. Available online: http://livertox.nlm.nih.gov/Herbals_and_Dietary_Supplements.htm (accessed on 7 November 2015).
48. Teschke, R.; Genthner, A.; Wolff, A.; Frenzel, C.; Schulze, J.; Eickhoff, A. Herbal hepatotoxicity: Analysis of cases with initially reported positive reexposure tests. Dig. Liver Dis. 2014, 46, 264-269. [CrossRef] [PubMed]
49. Teschke, R.; Frenzel, C.; Schulze, J.; Schwarzenboeck, A.; Eickhoff, A. Herbalife hepatotoxicity: Evaluation of cases with positive reexposure tests. World J. Hepatol. 2013, 5, 353-363. [CrossRef] [PubMed]
50. Teschke, R.; Frenzel, C. Drug induced liver injury: Do we still need a routine liver biopsy for diagnosis today? Ann. Hepatol. 2014, 13, 121-126.
51. Roytman, M.M.; Pörzgen, P.; Lee, C.L.; Huddleston, L.; Kuo, T.T.; Bryant- Greenwood, P.; Wong, L.L.; Tsai, N. Letter to the editor: Outbreak of severe hepatitis linked to weight-loss supplement OxyElite Pro. Am. J. Gastroenterol. 2014, 109, 1296-1298. [CrossRef] [PubMed]
52. Hennes, E.M.; Zeniya, M.; Czaja, A.J.; Parés, A.; Dalekos, G.N.; Krawitt, E.L.; Bittencourt, P.L.; Porta, G.; Boberg, K.M.; Hofer, H.; et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48, 169-176. [CrossRef] [PubMed]
53. Teschke, R.; Frenzel, C.; Schulze, J.; Eickhoff, A. Herbal hepatotoxicity: Challenges and pitfalls of causality assessment methods. World J. Gastroenterol. 2013, 19, 2864-2882. [CrossRef] [PubMed]
54. Fontana, R.J.;Watkins, P.B.; Bonkovsky, H.L.; Chalasani, N.; Davern, T.; Serrano, J.; Rochon, J. Drug-induced liver injury Network (DILIN) prospective study. Rationale, design and conduct. Drug Saf. 2009, 32, 55-68. [CrossRef] [PubMed]
55. Agarwal, V.K.; McHutchison, J.G.; Hoofnagle, J.H. Drug-Induced Liver Injury Network (DILIN). Important elements for the diagnosis of drug-induced liver injury. Clin. Gastroenterol. Hepatol. 2010, 8, 463-470. [CrossRef] [PubMed]
56. Naranjo, C.A.; Busto, U.; Sellers, E.M.; Sandor, P.; Ruiz, I.; Roberts, E.A.; Janecek, E.; Domecq, C.; Greenblatt, D.J. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 1981, 30, 239-245. [CrossRef] [PubMed]
57. World Health Organization (WHO). The Use of the WHO-UMC System for Standardised Case Causality Assessment. WHO Collaborating Centre for International Drug Monitoring (Uppsala Monitoring Centre, UMC), Database 2000. Available online: http://who-umc.org/Graphics/24734.pdf (accessed on 7 November 2015).
58. Kaplowitz, N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001, 33, 308-310. [CrossRef] [PubMed]
59. Karch, F.E.; Lasagna, L. Adverse drug reaction. A critical review. JAMA 1975, 234, 1236-1241. [CrossRef] [PubMed]
60. Teschke, R.; Schmidt-Taenzer, W.; Wolff, A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: Is the liver unspecific Naranjo scale precise enough to ascertain causality? Pharmacoepidemiol. Drug Saf. 2011, 20, 567-582. [CrossRef] [PubMed]
61. Teschke, R.; Schulze, J. Suspected herbal hepatotoxicity: Requirements for appropriate causality assessment by the US Pharmacopeia. Drug Saf. 2012, 35, 1091-1097. [CrossRef] [PubMed]
62. Teschke, R.; Schwarzenboeck, A.; Schmidt-Taenzer, W.; Wolff, A.; Hennermann, K.H. Herb induced liver injury presumably caused by black cohosh: A survey of initially purported cases and herbal quality specifications. Ann. Hepatol. 2011, 11, 249-259.
63. Teschke, R.; Schmidt-Taenzer, W.; Wolff, A. USP suspected herbal hepatotoxicity: Quality of causality assessment is more important than quantity of counted cases, not vice versa. Pharmacoepidemiol. Drug Saf. 2012, 21, 336-338. [CrossRef]
64. Mahady, G.B.; Low Dog, T.; Barrett, M.L.; Chavez, M.L.; Gardiner, P.; Ko, R.; Marles, R.J.; Pellicore, L.S.; Giancaspro, G.I.; Sarma, D.N. United States pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause 2008, 15, 628-638. [CrossRef] [PubMed]
65. Sarma, D.N.; Barrett, M.L.; Chavez, M.L.; Gardiner, P.; Ko, R.; Mahady, G.B.; Marles, R.J.; Pellicore, L.S.; Giancaspro, G.I.; Low Dog, T. Safety of green tea extract: A systematic review by the US pharmacopeia. Drug Saf. 2008, 31, 469-484. [CrossRef] [PubMed]
66. Teschke, R.; Wolff, A. Regulatory causality evaluation methods applied in kava hepatotoxicity: Are they appropriate? Regul. Toxicol. Pharmacol. 2011, 59, 1-7. [CrossRef] [PubMed]
67. World Health Organization (WHO). Assessments of the Risk of Hepatotoxicity with Kava Products; WHO Document Production Services: Geneva, Switzerland, 2007.
68. Björnsson, E.; Olsson, R. Suspected drug-induced liver fatalities reported to the WHO database. Dig. Liver Dis. 2006, 38, 33-38. [CrossRef] [PubMed]
69. Teschke, R.; Eickhoff, A.; Wolff, A.; Frenzel, C.; Schulze, J. Herbal hepatotoxicity and WHO global introspection method. Ann. Hepatol. 2013, 12, 11-21. [PubMed]
70. Teschke, R.; Frenzel, C.; Schulze, J.; Eickhoff, A. Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: Was causality adequately ascertained? Regul. Toxicol. Pharmacol. 2012, 63, 1-9. [CrossRef] [PubMed]
71. Teschke, R.; Frenzel, C.; Wolff, A.; Herzog, J.; Glass, X.; Schulze, J.; Eickhoff, A. Initially purported hepatotoxicity by Pelargonium sidoides: The dilemma of pharmacovigilance and proposals for improvements. Ann. Hepatol. 2012, 11, 500-512. [PubMed]
72. Rejection of Drug Risks, Step II. Available online: http://www.spc.int/cis/documents/02_0714_BfArM_ Kava_Removal.pdf (accessed on 7 November 2015).
73. Teschke, R.; Glass, X.; Schulze, J. Herbal hepatotoxicity by Greater Celandine (Chelidonium majus): Causality assessment of 22 spontaneous reports. Regul. Toxicol. Pharmacol. 2011, 61, 282-291. [CrossRef] [PubMed]
74. Klontz, K.C.; DeBeck, H.J.; LeBlanc, P.; Mogen, K.M.; Wolpert, B.J.; Sabo, J.L.; Salter, M.; Seelman, S.L.; Lance, S.E.; Monahan, C.; et al. The role of adverse event reporting in the FDA response to multistate outbreak of liver disease associated with a dietary supplement. Public Health Rep. 2015, 130, 526-532. [PubMed]
75. Teschke, R. Black cohosh and suspected hepatotoxicity-Inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm: A critical review. Menopause 2010, 17, 426-440. [CrossRef] [PubMed]
76. García-Cortés, M.; Lucena, M.I.; Pachkoria, K.; Borraz, Y.; Hidalgo, R.; Andrade, R.J. Evaluation of Naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment. Pharmacol. Ther. 2008, 27, 780-789. [CrossRef] [PubMed]
77. Tajiri, K.; Shimizu, Y. Practical guideline for diagnosis and early management of drug-induced liver injury. World J. Gastroenterol. 2008, 14, 6774-6785. [CrossRef] [PubMed]
78. Fenkel, J.M.; Navarro, V.J. Herbal and dietary supplement-induced liver injury. Gastroenterol. Hepatol. 2011, 7, 695-696.
79. Wai, C.T. Presentation of drug-induced liver injury in Singapore. Singap. Med. J. 2006, 47, 116-120.
80. Björnsson, E.; Olsson, R. Serious adverse liver reactions associated with herbal weight loss supplements. J. Hepatol. 2007, 47, 295-297. [CrossRef] [PubMed]
81. European Medicine Agency (EMA). Assessment of Case Reports Connected to Herbal Medicinal Products Containing Cimicifugae Racemosae Rhizoma (Black Cohosh, Root). Available online: http://www. ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2010/02/WC500074167.pdf (accessed on 7 November 2015).
82. García-Cortés, M.; Borraz, Y.; Lucena, M.I.; Peláez, G.; Salmerón, J.; Diago, M.; Martínez-Sierra, M.C.; Navarro, J.M.; Planas, R.; Soria, M.J.; et al. Liver injury induced by "natural remedies": An analysis of cases submitted to the Spanish Liver Toxicity Registry. Rev. Esp. Enferm. Dig. 2008, 100, 688-695. [PubMed]
83. Daly, A.K.; Donaldson, P.T.; Bhatnagar, P.; Shen, Y.; Pe'er, I.; Floratos, A.; Daly, M.J.; Goldstein, D.B.; John, S.; Nelson, M.R.; et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 2009, 41, 816-819. [CrossRef] [PubMed]
84. Miljkovic, M.M.; Dobric, S.; Dragojevic-Simic, V. Consistency between causality assessments obtained with two scales and their agreement with clinical judgments in hepatotoxicity. Pharmacoepidemiol. Drug Saf. 2011, 20, 272-285. [CrossRef] [PubMed]
85. Jung, K.A.; Min, H.J.; Yoo, S.S.; Kim, H.J.; Choi, S.N.; Ha, C.Y.; Kim, H.J.; Kim, T.H.; Jung, W.T.; Lee, O.J.; et al. Drug-induced liver injury: Twenty five cases of acute hepatitis following ingestion of Polygonum multiflorum Thun. Gut Liver 2011, 5, 493-499. [CrossRef] [PubMed]
86. Chau, T.N.; Cheung, W.I.; Ngan, T.; Lin, J.; Lee, K.W.S.; Poon, W.T.; Leung, V.K.S.; Mak, T.; Tse, M.L. Causality assessment of herb-induced liver injury using multidisciplinary approach and the Roussel Uclaf Causality assessment Method (RUCAM). Clin. Toxicol. 2011, 49, 34-39. [CrossRef] [PubMed]
87. Lucena, M.I.; Molokhia, M.; Shen, Y.; Urban, T.J.; Aithal, G.P.; Andrade, R.J.; Day, C.P.; Ruiz-Cabello, F.; Donaldson, P.T.; Stephens, C.; et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011, 141, 338-347. [CrossRef] [PubMed]
88. Miljkovic, M.M.; Dobric, S.; Dragojevic-Simic, V. Accuracy and reproducibility of two scales in causality assessment of unexpected hepatotoxicity. J. Clin. Pharm. Ther. 2012, 37, 196-203. [CrossRef] [PubMed]
89. Bessone, F.; Hernandez, N.; Dávalos, M.; Paraná, R.; Schinoni, M.I.; Lizarzabal, M.; Kershenobich, D.; Loaeza, A.; Arrese, M.; Chirino, R.A.; et al. Building a Spanish-Latin American network on drug induced liver injury; much to get from a joint collaborative initiative. Ann. Hepatol. 2012, 11, 544-549. [PubMed]
90. Cases of Liver Failure in Association with Flupirtine in the German Spontaneous Reporting System. Available online: http://www.akdae.de/Kommission/Organisation/Aufgaben/Publikationen/PDF/ Stammschulte2012.pdf (accessed on 7 November 2015).
91. Halegoua-De Marzio, D.; Vega, M.; Schifter Weber, J.; Aithal, G.P.; Andrade, R.J.; Bessone, F.; Bjornsson, E.; Bjornsson, H.K.; Larrey, D.G.; Lizarzabal, M.; et al. An international effort to assess hepatotoxicity associated with some herbalifer products. Hepatology 2013, 58, 383A-384A.
92. Douros, A.; Bronder, E.; Andersohn, F.; Klimpel, A.; Thomae, M.; Orzechowski, H.D.; Kreutz, R.; Garbe, E. Flupirtine-induced liver injury-Seven cases from the Berlin case-control surveillance study and review of the German spontaneous adverse drug reaction reporting database. Eur. J. Clin. Pharmacol. 2014, 70, 453-459. [CrossRef] [PubMed]
93. Robles-Diaz, M.; Gonzalez-Jimenez, A.; Medina-Caliz, I.; Stephens, C.; García-Cortes, M.; García-Muñoz, B.; Ortega-Alonso, A.; Blanco-Reina, E.; Gonzalez-Grande, R.; Jimenez-Perez, M.; et al. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Aliment. Pharmacol. Ther. 2015, 41, 116-125. [CrossRef] [PubMed]
94. Douros, A.; Bronder, E.; Andersohn, F.; Klimpel, A.; Thomae, M.; Sarganas, G.; Kreutz, R.; Garbe, E. Drug-induced liver injury: Results from the hospital-based Berlin case-control surveillance study. Br. J. Clin. Pharmacol. 2015, 79, 988-999. [CrossRef] [PubMed]
95. Johnstone, D.I.; Chang, A.; Viray, M.; Chatham-Stephens, K.; He, H.; Taylor, E.; Wong, L.L.; Schier, J.; Martin, C.; Fabricant, D.; et al. Hepatotoxicity associated with the dietary supplement OxyELITE Pro™-Hawaii 2013. Drug Test Anal. 2015. [CrossRef] [PubMed]
96. Flamenbaum, M.; Abergel, A.; Marcato, N.; Zénut, M.; Kémény, J.L.; Cassan, P. Regressive fulminant hepatitis, acute pancreatitis and renal insufficiency after taking ketoprofen. Gastroenterol. Clin. Biol. 1998, 22, 975. [PubMed]
97. Lucena, M.I.; Carvajal, A.; Andrade, R.J.; Velasco, A. Antidepressant-induced hepatotoxicity. Expert Opin. Drug Saf. 2003, 2, 249-262. [CrossRef] [PubMed]
98. Stickel, F.; Baumüller, H.M.; Seitz, K.; Vasilakis, D.; Seitz, G.; Seitz, H.K.; Schuppan, D. Hepatitis induced by Kava (Piper methysticum rhizoma). J. Hepatol. 2003, 39, 62-67. [CrossRef]
99. Masumoto, T.; Horiike, N.; Abe, M.; Kumaki, T.; Matsubara, H.; Fazle Akbar, S.M.; Michitaka, K.; Hyodo, I.; Onji, M. Diagnosis of drug-induced liver injury in Japanese patients by criteria of the Consensus Meetings in Europe. Hepatol. Res. 2003, 25, 1-7. [CrossRef]
100. Andrade, R.J.; Lucena, M.I.; Alonso, A.; García-Cortes, M.; García-Ruiz, E.; Benitez, R.; Fernández, M.C.; Pelaez, G.; Romero, M.; Corpas, R.; et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 2004, 39, 1603-1612. [CrossRef] [PubMed]
101. Arotcarena, R.; Bigué, J.P.; Etcharry, F.; Pariente, A. Pioglitazone-induced acute severe hepatitis. Gastroenterol. Clin. Biol. 2004, 28, 609-618.
102. Lee,W.M.; Larrey, D.; Olsson, R.; Lewis, J.H.; Keisu, M.; Auclert, L.; Sheth, S. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf. 2005, 28, 351-370. [CrossRef] [PubMed]
103. Jorge, O.A.; Jorge, A.D. Hepatotoxicity associated with the ingestion of Centella asiatica. Rev. Esp. Enferm. Dig. 2005, 97, 115-124. [CrossRef] [PubMed]
104. Gloro, R.; Hourmand-Ollivier, I.; Mosquet, B.; Mosquet, L.; Rousselot, P.; Salamé, E.; Piquet, M.A.; Dao, T. Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea. Eur. J. Gastroenterol. Hepatol. 2005, 17, 1135-1137. [CrossRef] [PubMed]
105. Fontana, R.J.; Shakil, O.; Greenson, J.K.; Boyd, I.; Lee, W.M. Acute liver failure due to amoxicillin and amoxicillin/clavulanate. Dig. Dis. Sci. 2005, 10, 1785-1790. [CrossRef] [PubMed]
106. De Valle, M.B.; Klinteberg, V.; Alem, N.; Olsson, R.; Björnsson, E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment. Pharmacol. Ther. 2006, 24, 1187-1195. [CrossRef] [PubMed]
107. Yuen, M.F.; Tam, S.; Fung, J.; Wong, D.K.H.; Wong, B.C.Y.; Lai, C.L. Traditional Chinese Medicine causing hepatotoxicity in patients with chronic hepatitis B infection: A 1-year prospective study. Aliment. Pharmacol. Ther. 2006, 24, 1179-1186. [CrossRef] [PubMed]
108. Jimenez-Saenz, M.; Martinez-Sanchez M del, C. Acute hepatitis associated with the use of green tea infusions. J. Hepatol. 2006, 44, 616-617. [CrossRef] [PubMed]
109. Cárdenas, A.; Restrepo, J.C.; Sierra, F.; Correa, G. Acute hepatitis due to shen-min: Aherbal product derived from Polygonum multiflorum. J. Clin. Gastroenterol. 2006, 40, 629-632. [CrossRef] [PubMed]
110. Yan, B.; Leung, Y.; Urbanski, S.J.; Myers, R.P. Rofecoxib-induced hepatotoxicity: A forgotten complication of the coxibs. Can. J. Gastroenterol. 2006, 20, 351-355. [PubMed]
111. Hussaini, S.H.; O'Brien, C.S.; Despott, E.J.; Dalton, H.R. Antibiotic therapy: A major cause of drug-induced jaundice in southwest England. Eur. J. Gastroenterol. Hepatol. 2007, 19, 15-20. [CrossRef] [PubMed]
112. Stojanovski, S.D.; Casavant, M.J.; Mousa, H.M.; Baker, P.; Nahata, M.C. Atomoxetine-induced hepatitis in a child. Clin. Toxicol. 2007, 45, 51-55. [CrossRef]
113. Björnsson, E.; Kalaitzakis, E.; Klinteberg, V.A.V.; Alem, E.; Olsson, R. Long-term follow-up of patients with mild to moderate drug-induced liver injury. Alimdnt. Pharmacol. 2007, 26, 79-85. [CrossRef] [PubMed]
114. Rigato, I.; Cravatari, M.; Avellini, C.; Ponte, E.; Crocè, S.L.; Tiribelli, C. Drug-induced acute cholestatic liver damage in a patient with mutation of UGT1A1. Nat. Clin. Pract. Gastroenterol. Hepatol. 2007, 4, 403-408. [CrossRef] [PubMed]
115. Teschke, R.; Schwarzenboeck, A.; Hennermann, K.H. Kava hepatotoxicity: A clinical survey and critical analysis of 26 suspected cases. Eur. J. Gastroenterol. Hepatol. 2008, 20, 1182-1193. [CrossRef] [PubMed]
116. Kang, S.H.; Kim, J.I.; Jeong, K.H.; Ko, K.H.; Ko, P.G.; Hwang, S.W.; Kim, E.M.; Kim, S.H.; Lee, H.Y.; Lee, B.S. Clinical characteristics of 159 cases of acute toxic hepatitis. Korean J. Hepatol. 2008, 14, 483-492. [CrossRef] [PubMed]
117. Sohn, C.H.; Cha, M.I.; Oh, B.J.; Yeo,W.H.; Lee, J.H.; Kim,W.; Lim, K.S. Liver transplantation for acute toxic hepatitis due to herbal medicines and preparations. J. Korean Soc. Clin. Toxicol. 2008, 6, 110-116.
118. Choi, G.Y.; Yang, H.W.; Cho, S.H.; Kang, D.W.; Go, H.; Lee, W.C.; Lee, Y.J.; Jung, S.H.; Kim, A.N.; Cha, S.W. Drug-induced hepatitis caused by albendazole. J. Korean Med. Sci. 2008, 23, 903-905. [CrossRef] [PubMed]
119. Teschke, R.; Bahre, R. Severe hepatotoxicity by Indian Ayurvedic herbal products: A structured causality assessment. Ann. Hepatol. 2009, 8, 258-266. [PubMed]
120. Mazzanti, G.; Menniti-Ippolito, F.; Moro, P.A.; Cassetti, F.; Raschetti, R.; Santuccio, C.; Mastrangelo, S. Hepatotoxicity from green tea: A review of the literature and two unpublished cases. Eur. J. Clin. Pharmacol. 2009, 65, 331-341. [CrossRef] [PubMed]
121. Stickel, F.; Droz, S.; Patsenker, E.; Bögli-Stuber, K.; Aebi, B.; Leib, S.L. Severe hepatotoxicity following ingestion of Herbalife nutritionally supplements contaminated with Bacillus subtilis. J. Hepatol. 2009, 50, 111-117. [CrossRef] [PubMed]
122. Kang, H.S.; Choi, H.S.; Yun, T.J.; Lee, K.G.; Seo, Y.S.; Yeon, J.E.; Byun, K.S.; Um, S.H.; Kim, C.D.; Ryu, H.S. A case of acute cholestatic hepatitis induced by Corydalis speciosa Max. Korean J. Hepatol. 2009, 15, 517-523. [CrossRef] [PubMed]
123. Teschke, R.; Schwarzenboeck, A. Suspected hepatotoxicity by cimicifugae racemosae rhizoma (black cohosh, root): Critical analysis and structured causality assessment. Phytomedicine 2009, 16, 72-84. [CrossRef] [PubMed]
124. Teschke, R.; Bahre, R.; Fuchs, J.;Wolff, A. Black cohosh hepatotoxicity: Quantitative causality evaluation in nine suspected cases. Menopause 2009, 16, 956-965. [CrossRef] [PubMed]
125. Kim, S.Y.; Yim, H.J.; Ahn, J.H.; Kim, J.H.; Kim, J.N.; Yoon, I.; Kim, D.I.; Lee, H.S.; Lee, S.W.; Choi, J.H. Two cases of toxic hepatitis caused by arrowroot juice. Korean J. Hepatol. 2009, 15, 504-509. [CrossRef] [PubMed]
126. Harugeri, A.; Parthasarathi, G.; Sharma, J.; D'Souza, G.A.; Ramesh, M. Montelukast induced acute hepatocellular injury. J. Postgrad. Med. 2009, 55, 141-142. [PubMed]
127. Licata, A.; Calvaruso, V.; Capello, M.; Craxi, A.; Almasio, P.L. Clinical course and outcomes of drug-induced liver injury: Nimesulide as the first implicated medication. Dig. Liver Dis. 2010, 42, 143-148. [CrossRef] [PubMed]
128. Essaid, A.; Timraz, A. Cholestatic acute hepatitis induced by tadalafil (Cialisr). Gastroenterol. Clin. Biol. 2010, 34, e1-e2. [CrossRef] [PubMed]
129. Jóhannsson, M.; Ormarsdóttir, S.; Olafsson, S. Hepatotoxicity associated with the use of Herbalife. Laeknabladid 2010, 96, 167-172. [PubMed]
130. Bae, S.H.; Kim, D.H.; Bae, Y.S.; Lee, K.J.; Kim, D.W.; Yoon, J.B.; Hong, J.H.; Kim, S.H. Toxic hepatitis associated with Polygoni multiflori. Korean J. Hepatol. 2010, 16, 182-186. [CrossRef] [PubMed]
131. Treeprasertsuk, S.; Huntrakul, J.; Ridtitid, W.; Kullavanijaya, P.; Björnsson, E.S. The predictors of complications in patients with drug-induced liver injury caused by antimicrobial agents. Aliment. Pharmacol. Ther. 2010, 11, 1200-1207. [CrossRef] [PubMed]
132. Yang, H.N.; Kim, D.J.; Kim, Y.M.; Kim, B.H.; Sohn, K.M.; Choi, M.J.; Choi, Y.H. Aloe-induced toxic hepatitis. J. Korean Med. Sci. 2010, 25, 492-495. [CrossRef] [PubMed]
133. Singla, A.; Hammad, H.T.; Hammoud, G.M. Uncommon cause of acute drug-induced liver injury following mammoplasty. Gastroenterol. Res. 2010, 3, 171-172. [CrossRef]
134. Teschke, R. Kava hepatotoxicity: A clinical review. Ann. Hepatol. 2010, 9, 251-265. [PubMed]
135. Lin, G.; Wang, J.Y.; Li, N.; Li, M.; Gao, H.; Ji, Y.; Zhang, F.; Wang, H.; Zhou, Y.; Ye, Y.; et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J. Hepatol. 2011, 54, 666-673. [CrossRef] [PubMed]
136. Gluck, N.; Fried, M.; Porat, R. Acute amiodarone liver toxicity likely due to ischemic hepatitis. Isr. Med. Assoc. J. 2011, 13, 748-752. [PubMed]
137. Sabaté, M.; Ibáñez, L.; Pérez, E.; Vidal, X.; Buti, M.; Xiol, X.; Mas, A.; Guarner, C.; Forné, M.; Solà, R.; et al. Paracetamol in therapeutic dosages and acute liver injury: Causality assessment in a prospective case series. BMC Gastroenterol. 2011, 11, 80. [CrossRef] [PubMed]
138. Timcheh-Hariri, A.; Balali-Mood, M.; Aryan, E.; Sadeghi, M.; Riahi-Zanjani, B. Toxic hepatitis in a group of 20 male body-builders taking dietary supplements. Food Chem. Toxicol. 2012, 50, 3826-3832. [CrossRef] [PubMed]
139. Teschke, R.; Frenzel, C.; Glass, X.; Schulze, J.; Eickhoff, A. Greater Celandine hepatotoxicity: A clinical review. Ann. Hepatol. 2012, 11, 838-848. [PubMed]
140. Moch, C.; Rocher, F.; Lainé, P.; Lacotte, J.; Biour, M.; Gouraud, A.; Bernard, N.; Descotes, J.; Vial, T. Etifoxine-induced acute hepatitis: A case series. Clin. Res. Gastroenterol. Hepatol. 2012, 36, e85-e88. [CrossRef] [PubMed]
141. Kim, Y.J.; Ryu, S.L.; Shim, J.W.; Kim, D.S.; Shim, J.Y.; Park, M.S.; Jung, H.L. A pediatric case of toxic hepatitis induced by Hovenia dulcis. Pediatr. Gastroenterol. Hepatol. Nutr. 2012, 15, 111-116. [CrossRef]
142. Gao, H.; Li, N.; Wang, J.Y.; Zhang, S.C.; Lin, G. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. J. Dig. Dis. 2012, 13, 33-39. [CrossRef] [PubMed]
143. Sprague, D.; Bamha, K. Drug-induced liver injury due to varenicline. BMC Gastroenterol. 2012, 12, 65. [CrossRef] [PubMed]
144. Suk, K.T.; Kim, D.J.; Kim, C.H.; Park, S.H.; Yoon, J.H.; Kim, Y.S.; Baik, G.H.; Kim, J.B.; Kweon, Y.O.; Kim, B.I.; et al. A prospective nationwide study of drug-induced liver injury in Korea. Am. J. Gastroenterol. 2012, 107, 1380-1387. [CrossRef] [PubMed]
145. Hou, F.Q.; Zeng, Z.; Wang, G.Q. Hospital admissions for drug-induced liver injury: Clinical features, therapy, and outcomes. Cell Biochem. Biophys. 2012, 64, 77-83. [CrossRef] [PubMed]
146. Nabha, L.; Balba, G.P.; Tuanzon, C.; Kumar, P.N. Etravirine induced severe hpersensitivity reaction and fulminant hepatitis: A case report and review of the literature. J. AIDS Clin. Res. 2012. [CrossRef]
147. Ripault, M.P.; Pinzani, V.; Fayolle, V.; Pageaux, G.P.; Larrey, D. Crizotinib-induced acute hepatitis: First case with relaps after reintroduction with reduced dose. Clin. Res. Gastroenterol. Hepatol. 2013, 37, e21-e23. [CrossRef] [PubMed]
148. Carrier, P.; Godet, B.; Crepin, S.; Magy, L.; Debette-Gratien, M.; Pillegand, B.; Jacques, J.; Sautereau, D.; Vidal, E.; Labrousse, F.; et al. Acute liver toxicity due to methylprednisolone: Consider this diagnosis in the context of autoimmunity. Clin. Res. Gastroenterol. Hepatol. 2013, 37, 100-104. [CrossRef] [PubMed]
149. Ríos, D.; Restrepo, J.C. Abendazole-induced liver injury: A case report. Colomb. Med. 2013, 44, 118-120. [PubMed]
150. Goossens, N.; Spahr, L.; Rubbia-Brandt, L. Severe immune-mediated drug-induced liver injury linked to ibandronate: A case report. J. Hepatol. 2013, 59, 1139-1142. [CrossRef] [PubMed]
151. Markova, S.M.; de Marco, T.; Bendjilali, N.; Kobashigawa, E.A.; Mefford, J.; Sodhi, J.; Le, H.; Zhang, C.; Halladay, J.; Rettie, A.E.; et al. Association of CYP2C9*2 with bosentan-induced liver injury. Clin. Pharmacol. Ther. 2013, 94, 678-686. [CrossRef] [PubMed]
152. Abenavoli, L.; Milic, N.; Beaugrand, M. Severe hepatitis by cyproterone acetate: Role of corticosteroids. A case report. Ann. Hepatol. 2013, 1, 152-155.
153. Björnsson, E.S.; Bergmann, O.M.; Björnsson, H.K.; Kvaran, R.B.; Olafsson, S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013, 144, 1419-1425. [CrossRef] [PubMed]
154. Marumoto, A.; Roytman, M.M.; Tsai, N.C.S. Trial and error: Investigational drug induced liver injury, a case series report. Hawaiì J. Med. Public Health 2013, 72, 30-33. [PubMed]
155. Adnan, M.M.; Khan, M.; Hashmi, S.; Hamza, M.; AbdulMujeeb, S.; Amer, S. Black cohosh and liver toxicity: Is there a relationship? Case Rep. Gastrointest. Med. 2014. [CrossRef]
156. Lin, J.; Moore, D.; Hockey, B.; Di Lernia, R.; Gorelik, A.; Liew, D.; Nicoll, A. Drug-induced hepatotoxicity: Incidence of abnormal liver function tests consistent with volatile anaesthetic hepatitis in traumatic patients. Liver Intern. 2014, 34, 576-586. [CrossRef] [PubMed]
157. Cheetham, T.C.; Lee, J.; Hunt, C.M.; Niu, F.; Reisinger, S.; Murray, R.; Powell, G.; Papay, J. An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record data. Pharmacoepidemiol. Drug Saf. 2014, 23, 601-608. [CrossRef] [PubMed]
158. Russmann, S.; Niedrig, D.F.; Budmiger, M.; Schmidt, C.; Stieger, B.; Hürlimann, S.; Kullak-Ublick, G.A. Rivaroxaban postmarketing risk of liver injury. J. Hepatol. 2014, 61, 293-300. [CrossRef] [PubMed]
159. Bohm, N.; Bohm, N.; Makowski, C.; Machado, M.; Davie, A.; Seabrook, N.; Wheless, L.; Bevill, B.; Clark, B.; Kyle, T.R., III. Case report and cohort analysis of drug-induced liver injury associated with daptomycin. Antimicrobial. Agents Chemother. 2014, 58, 4902-4903. [CrossRef] [PubMed]
160. Saiful-Islam, M.; Wright, G.; Tanner, P.; Lucas, R. A case of anastrazole-related drug-induced autoimmune hepatitis. Clin. J. Gastroenterol. 2014, 7, 414-417. [CrossRef] [PubMed]
161. Im, S.G.; Yoo, S.H.; Jeon, D.O.; Cho, H.J.; Choi, J.Y.; Paik, S.; Park, Y.M. Chelidonium majus-induced acute hepatitis. Ewha Med. J. 2014, 37, 60-63. [CrossRef]
162. Lim, R.; Choundry, H.; Conner, K.; Karnsakul, W. A challenge for diagnosing acute liver injury with concomitant/sequential exposure to multiple drugs: Can causality assessment scales be utilized to identify the offending drug? Case Rep. Pediatr. 2014, 2014, 156389. [CrossRef] [PubMed]
163. Hao, K.; Yu, Y.; He, C.; Wang, M.; Wang, S.; Li, X. RUCAM scale-based diagnosis, clinical features and prognosis of 140 cases of drug-induced liver injury. J. Zhonghua Gan Zang Bing 2014, 22, 938-994.
164. Veluswamy, R.R.;Ward, S.C.; Yum, K.; Abramovitz, R.B.; Isola, L.M.; Jagannath, S.; Parekh, S. Adverse drug reaction: Pomalidomide-induced liver injury. Lancet 2014, 383, 2125-2126. [CrossRef]
165. Lin, P.F. A Case of Amoxicillin Hepatocellular Injury. Available online: http://www.med.ucla.edu/ modules/xfsection/article.php?articleid=804 (accessed on 7 November 2015).
166. Dyson, J.K.; Hutchinson, J.; Harrison, L.; Rotimi, O.; Tiniakos, D.; Foster, G.R.; Aldersley, M.A.; McPherson, S. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J. Hepatol. 2015. [CrossRef] [PubMed]
167. Yilmaz, B.; Yilmaz, B.; Aktaş, B.; Unlu, O.; Roach, E.C. Lesser celandine (pilewort) induced acute toxic liver injury: The first case report worldwide. World J. Hepatol. 2015, 7, 285-288. [CrossRef] [PubMed]
168. Mazzanti, G.; Di Soto, A.; Vitalone, A. Hepatotoxicity of green tea: An update. Arch. Toxicol. 2015, 89, 1175-1191. [CrossRef] [PubMed]
169. Tauqeer, A.; Pandey, R.; Shah, R.; Black, J. Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. BMJ Case Rep. 2015. [CrossRef]
170. Son, C.G. Drug-induced liver injury byWestern medication. J. Int. Korean Med. 2015, 36, 69-75.
171. Baig, M.;Wool, K.J.; Halalnych, J.H.; Sarmad, R.A. Acute liver failure after initiation of rivaroxaban: A case report and review of the literature. N. Am. J. Med. Sci. 2015, 7, 407-410. [CrossRef] [PubMed]
172. Tang, D.M.; Koh, C.; Twaddell, W.S.; von Rosenvinge, E.C.; Han, H. Acute hepatocellular drug-induced liver injury from bupropion and doxycycline. ACG Case Rep. J. 2015, 3, 66-68. [CrossRef] [PubMed]
173. Woo, H.J.; Kim, H.Y.; Choi, E.S.; Cho, Y.; Kim, Y.; Lee, J.H.; Jang, E. Drug-induced liver injury: A 2-year retrospective study of 1169 hospitalized patients in a single medical center. Phytomedicine 2016, 22, 1201-1205. [CrossRef] [PubMed]